Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
Símbolo de cotizaciónQTRX
Nombre de la empresaQuanterix Corp
Fecha de salida a bolsaDec 07, 2017
Director ejecutivoToloue (Masoud)
Número de empleados471
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 07
Dirección900 Middlesex Turnpike
CiudadBILLERICA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal01821
Teléfono16173019400
Sitio Webhttps://www.quanterix.com/
Símbolo de cotizaciónQTRX
Fecha de salida a bolsaDec 07, 2017
Director ejecutivoToloue (Masoud)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos